P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
Jan Bewersdorf,
Helen Ajufo,
Claire Harrison,
Francesca Palandri,
John Mascarenhas,
Jeanne Palmer,
Aaron T. Gerds,
Jean-Jacques Kiladjian,
Andrii Derkach,
Karisse Roman-Torres,
Sarah Buckley,
Raajit K Rampal
Affiliations
Jan Bewersdorf
1 Memorial Sloan Kettering Cancer Center, New York, United States
Helen Ajufo
1 Memorial Sloan Kettering Cancer Center, New York, United States
Claire Harrison
2 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
Francesca Palandri
3 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
John Mascarenhas
4 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,, New York, United States
Jeanne Palmer
5 Mayo Clinic, Scottsdale, United States
Aaron T. Gerds
6 Cleveland Clinic Taussig Cancer Institute, Cleveland, United States
Jean-Jacques Kiladjian
7 Hôpital Saint-Louis, Université de Paris, Paris, France
Andrii Derkach
1 Memorial Sloan Kettering Cancer Center, New York, United States
Karisse Roman-Torres
8 CTI BioPharma Corp., Seattle, United States
Sarah Buckley
8 CTI BioPharma Corp., Seattle, United States
Raajit K Rampal
1 Memorial Sloan Kettering Cancer Center, New York, United States
